All In Biotech

Drug Trial Radar · NCT03164564

Evaluating the Safety and Efficacy of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

A Phase 3 Double Blind Safety and Efficacy Study of Long-Acting Injectable Cabotegravir Compared to Daily Oral TDF/FTC for Pre-Exposure Prophylaxis in HIV-Uninfected Women

Last checked: Nov 19, 2026Latest source record: Oct 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,224 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

3,224

Actual

Start

Nov 7, 2017

Primary completion

Nov 5, 2020

Study completion Oct 17, 2026

Sponsor

Sponsor type
NIH
First posted
May 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
Female only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of the long-acting injectable agent cabotegravir (CAB LA) compared to daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for pre-exposure prophylaxis (PrEP) in HIV-uninfected women.

Conditions

  • HIV Infections

Interventions

  • Oral CABDrug

    CAB 30 mg tablet

  • Oral TDF/FTCDrug

    TDF/FTC 300 mg/200 mg fixed dose combination tablet

  • Placebo for oral CABDrug

    Placebo tablets

  • Placebo for oral TDF/FTCDrug

    Placebo tablets

  • CAB LADrug

    600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle

  • Placebo for CAB LADrug

    Administered as one 3 mL intramuscular injection in the gluteal muscle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Pariicipants With Documented Incident HIV InfectionsTime frame: HIV tests at enrollment, weeks 2, 4, and 5, then every 4 weeks through week 25, then every 8 weeks. Analyzed through week 185 or the date of DSMB decision to unblind all participants, whichever is earliest.
  2. Number of Participants Who Experienced Grade 2 or Higher Clinical and Laboratory Adverse Events (AEs) in Steps 1 and 2Time frame: Treatment emergent AE measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks)

Locations

20 sites in 7 countries. Site status is shown where the registry gives one.

  • Gaborone CRS

    Gaborone, South-East District, Botswana

  • Eswatini Prevention Center CRS

    Mbabane, Eswatini

  • Kisumu Crs

    Kisumu, Nyanza, Kenya

  • Blantyre CRS

    Blantyre, Malawi

  • Malawi CRS

    Lilongwe, Central Region, Malawi

  • Soweto HPTN CRS

    Johannesburg, Gauteng, South Africa

  • Ward 21 CRS

    Johannesburg, Gauteng, South Africa

  • Botha's Hill CRS

    Durban, KwaZulu-Natal, South Africa

  • Isipingo CRS

    Isipingo, KwaZulu-Natal, South Africa

  • Verulam CRS

    Verulam, KwaZulu-Natal, South Africa

  • Desmond Tutu TB Centre - Stellenbosch University (DTTC-SU) CRS

    Cape Town, Western Cape, South Africa

  • Emavundleni CRS

    Cape Town, Western Cape, South Africa

  • UVRI-IAVI HIV Vaccine Program LTD. CRS

    Entebbe, Uganda

  • Baylor-Uganda CRS

    Kampala, Uganda

  • MU-JHU Research Collaboration (MUJHU CARE LTD) CRS

    Kampala, Uganda

  • Seke South CRS

    Chitungwiza, Zimbabwe

  • St Mary's CRS

    Chitungwiza, Zimbabwe

  • Milton Park CRS

    Harare, Zimbabwe

  • Spilhaus CRS

    Harare, Zimbabwe

  • Zengeza CRS

    Chitungwiza, Mashonaland East Province, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.